<DOC>
	<DOCNO>NCT00147303</DOCNO>
	<brief_summary>Sarpogrelate antiplatelet agent decrease 5-hydroxytryptamine ( 5-HT ) level platelet via blockade 5-HT2 receptor , use atherosclerotic peripheral arterial disease . The present double-blind control clinical pharmacology study perform 45 patient cerebral infarction , give 75 , 150 , 300 mg three time daily sarpogrelate 7 day order evaluate dose-response relationship term precisely measure inhibition platelet aggregation .</brief_summary>
	<brief_title>Effect Sarpogrelate Platelet Aggregation Patients With Cerebral Infarction : Dose-responsive Clinical Pharmacology Study</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Sarpogrelate</mesh_term>
	<criteria>1 . Cerebral infarction except cardiac source embolism base NINDSⅢclassification 2 . Neurological sign persisting≧ 1 day onset 3 . Defined onset symptom , stable condition period enrollment 4 . CT MRI detection responsible site 5. age≧20 6 . Systolic pressure≦180 mmHg , Diastolic pressure≦110 mmHg 7 . The maximum intensity platelet aggregation 15 % induced serotonin ( 1µM ) epinephrine ( 3µM ) day prior first medication 8 . Written informed consent must obtain patient enrollment study 1 . Functional outcome randomization : Modified Rankin Scale=4 , 5 2 . Previous plan vascular surgery cerebral infarction 3 . History intracranial hemorrhage 4 . History systemic bleeding , history bleed diathesis coagulopathy 5 . With severe complication ( renal hepatic insufficiency , heart failure , hemopathy , ) 6 . Treating malignant tumor 7 . Pregnant possibly pregnant woman , nurse mother 8 . History sarpogrelate sensitivity 9 . Previously enter clinical trial within 3 month 10 . Less 3 month since clinical trial 11 . Judged investigator unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>